1. Dear Drugs-Forum readers: We are a small non-profit that runs one of the most read drug information & addiction help websites in the world. We serve over 4 million readers per month, and have costs like all popular websites: servers, hosting, licenses and software. To protect our independence we do not run ads. We take no government funds. We run on donations which average $25. If everyone reading this would donate $5 then this fund raiser would be done in an hour. If Drugs-Forum is useful to you, take one minute to keep it online another year by donating whatever you can today. Donations are currently not sufficient to pay our bills and keep the site up. Your help is most welcome. Thank you.
    PLEASE HELP

1-Pentyl-3-phenylacetylindoles, a new class of cannabimimetic indoles (2005)

1-Pentyl-3-phenylacetylindoles, a new class of cannabimimetic indoles (2005)

  1. ThirdEyeFloond
    John W. Huffman, Paul V. Szklennik, Amanda Almond, Kristen Bushell, Dana E. Selley, Hengjun Heb, Michael P. Cassidy, Jenny L. Wiley and Billy R. Martin

    The synthesis and pharmacology of 30 1-pentyl-3-arylacetylindoles (R = H and CH3) are described. Two of these compounds are highly efficacious and selective ligands for the CB1 receptor.


    Abstract
    A new class of cannabimimetic indoles, with 3-phenylacetyl or substituted 3-phenylacetyl substituents, has been prepared and their affinities for the cannabinoid CB1 and CB2 receptors have been determined. In general those compounds with a 2-substituted phenylacetyl group have good affinity for both receptors. The 4-substituted analogs have little affinity for either receptor, while the 3-substituted compounds are intermediate in their affinities. Two of these compounds, 1-pentyl-3-(2-methylphenylacetyl)indole (JWH-251) and 1-pentyl-3-(3-methoxyphenylacetyl)indole (JWH-302), have 5-fold selectivity for the CB1 receptor with modest affinity for the CB2 receptor. GTPĪ³S determinations indicate that both compounds are highly efficacious agonists at the CB1 receptor and partial agonists at the CB2 receptor.